Antimicrobial peptides (AMPs), such as β-defensins and cathelicidins, are essential components of innate and adaptive immunity owing to their extensive multifunctional activities. However, their role in fungal infection in vivo remains elusive. In this study, we investigated the protective effect of murine β-defensin 3 (mBD3), mBD4, and the cathelicidin cathelin-related antimicrobial peptide (CRAMP) in a murine model of Fusarium solani keratitis. C57BL/6 mice showed significant corneal disease 1 and 3 days after infection, which was accompanied by enhanced expression of β-defensins and CRAMP. Disease severity was significantly improved 7 days after infection, at which time AMP expression was returning to baseline. Mice deficient in mBD3 (genetic knockout), mBD4 (short interfering RNA knockdown), or CRAMP (genetic knockout) exhibited enhanced disease severity and progression, increased neutrophil recruitment, and delayed pathogen elimination compared to controls. Taken together, these data suggest a vital role for AMPs in defense against F. solani keratitis, a potentially blinding corneal disease.

Fungal keratitis (keratomycosis), which is more common in warmer, humid climates, is a potentially devastating ocular infection. It is characterized by epithelial edema and intense stromal inflammation which, if untreated, can lead to corneal scarring, profound vision loss, and possibly endophthalmitis (1–3). While a range of fungi may be the culprit, Fusarium species are the most commonly isolated organisms, with Fusarium solani being implicated as the causative pathogen in more than 30% of cases (2–4). Ocular trauma and contact lens wear have long been recognized as the major predisposing factors for fungal keratitis, with F. solani being the culprit in the 2004-2006 worldwide epidemic associated with contact lens wear (5, 6). Little emphasis had been placed on the study of the host-pathogen response until quite recently. A breach in the corneal epithelium facilitates entry of conidia, which germinate, and the hyphae penetrate the corneal stroma, initiating an immune response mediated via toll-like receptors (TLRs) and Dectin-1 (7–10). Standard antifungal treatments are most effective if given early, but overall, fungal keratitis is notoriously difficult to treat, a problem further exacerbated by the appearance of drug-resistant strains (11, 12).

In an effort to offer novel interventional opportunities, it is imperative that we obtain a better understanding of the pathology, host response, and endogenous defense mechanisms related to Fusarium-induced keratitis. Antimicrobial peptides (AMPs), such as defensins and cathelicidins, are small cationic molecules with roles in pathogen killing, immunomodulation, and wound healing, among others (13, 14). Studies show that these endogenous molecules have potent antifungal activity, primarily via their membrane perturbation effects, but modulation of intracellular pathways may be involved (15–19). AMP immunomodulatory effects also raise the possibility of a protective effect without direct fungicidal killing (14, 20, 21).

Defensins and cathelicidin are produced by the ocular surface epithelia and by immune and inflammatory cells infiltrating the eye in response to infection (22). Recent in vivo studies in a murine model of bacterial keratitis have shown that deficiency (either by transient silencing by short interfering RNA [siRNA] or gene knockout [KO]) of mouse β-defensin 2 (mBD2) or mBD3 (homolog of human β-defensin 2) or the cathelicidin cathelin-related antimicrobial peptide (CRAMP) (homolog of human LL37) results in more severe infection and tissue damage (23–26). Further, exposure to Candida albicans significantly upregulated the expression of CRAMP (27), and mice deficient in CRAMP were more susceptible to Candida keratitis than wild-type (WT) mice (28). These studies show an essential role for AMPs in protection against Pseudomonal and Candida keratitis. However, despite being the most common cause of fungal keratitis, little is known about the role of AMPs in the innate immune response to Fusarium. Therefore, this study focused on establishing a role for mouse β-defensins and CRAMP in F. solani-induced keratitis in vivo.

MATERIALS AND METHODS

Fungi. F. solani (strain 36031; American Type Culture Collection, Manassas, VA), a strain capable of producing murine keratomycosis (29), was cultured in Sabouraud dextrose (SD) agar (Difco, Detroit, MI) for 3 days at 30°C. A colony of F. solani was inoculated into 4 ml of SD broth and grown aerobically overnight at 30°C, 250 rpm. Five hundred μl of fungal suspension was inoculated into 50 ml of fresh SD broth at 30°C, 250 rpm for 48 h to expand the culture. The conidia were harvested by filtering out the hyphae by passing the culture through sterile phosphate buffer (PB)-soaked gauze held in front of a 30-ml syringe. The turbidity of the suspension was adjusted to an optical density (OD) of 1 at 600 nm, which corresponds to $5 \times 10^{5}$ culturable units (CU) (30). The conidial suspension then was concentrated by centrifuging at 300 x g for 10 min, resuspended in media to yield $1 \times 10^{5}$ CU/μl, and used to induce experimental keratomycosis in mice as described below.

Experimental animals. Inbred mixed-sex, age-matched, 6- to 8-week-old mice of the following genotypes were used: C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME), CRAMP KO mice (Cnlp−/−) on the...
C57 background (31), and homozygous WT (Defb3+/+) and mBD3 KO (Defb3-/-) mice on the C57 background that were custom generated by Xenogen Biosciences, now Taconic, Hudson, NY. Genotypes for C57L/J, C57BL/6, WT, and KO mBD3 mice were confirmed by standard PCR analysis done on DNA isolated from tail clips. In vivo knockdown of mBD4 was achieved using a method previously described by Wu et al. using siRNA purchased from Santa Cruz Biotechnology (24). Briefly, 5 μl of 8 μM mBD4 siRNA or scrambled control siRNA was injected subconjunctivally into the right eye of C57BL/6 mice 1 day prior to fungal challenge. Topical application of 5 μl of 4 μM siRNA/mouse was performed once on the day of infection following fungal inoculation. The topical application was then repeated every 12 h for 2 days following infection. Silencing of mBD4 was confirmed by relative quantitative reverse transcription-PCR (RT-PCR) and immunostaining as described below. All protocols used were approved by the University of Houston Institutional Animal Care and Use Committee and were in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

**Experimental keratocystis.** Wild-type and mutant mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg of body weight) and xylazine (10 mg/kg) (Vedco, Inc., St. Joseph, MO) and then placed beneath a surgical stereomicroscope. The cornea of the right eye was scratched with a sterile 27-gauge needle. Three parallel 1-mm scratches were made in the central cornea so as to abrade the full thickness of the epithelium and penetrate the superficial stroma. A 5-μl aliquot containing 1 × 10⁶ CFU of F. solani was pipetted directly onto the scarified cornea. The clinical progression of infection was monitored, and the extent of corneal damage was evaluated and documented by digital imaging using a slit lamp equipped with camera module CM 01 (Haag Streit USA, Mason, OH) at days 1, 3, and 7 postinfection (p.i.). The progression of infection was graded using a scale previously established by Wu et al. (30), where a grade of 0 to 4 is assigned for each of three criteria: area of opacity, density of opacity, and surface regularity. The scores from all three categories were summed to obtain a total possible score ranging from 0 to 12. A total score of 3 or less represented mild eye disease, 6 to 9 represented moderate disease, and more than 9 was categorized as severe disease.

**Fungal load and myeloperoxidase assay.** The fungal load was measured as previously described (32). Control and infected corneas from two to four mice were harvested at days 1, 3, and 7 p.i. and homogenized (8 to 10 strokes for 10 s, repeated 3 times until all tissue was uniformly homogenized) on ice in 1 ml of sterile phosphate-buffered saline (PBS), pH 7.4. A 100-μl aliquot of the homogenate was serially diluted in sterile PBS, and duplicate aliquots were plated onto SD agar plates, which were incubated for 48 to 72 h at 37°C, and then the number of culturable units was counted. The remaining homogenate was processed to quantitate the number of infiltrating neutrophils by myeloperoxidase (MPO) activity.

MPO determination is a standard and well-established method for assessing neutrophil activity in infectious keratitis (33). To determine MPO activity, hexadecyltrimethylammonium bromide at a final concentration of 0.5% (wt/vol) in 50 mM phosphate buffer (pH 6.0) was added to 90 μl corneal homogenate. Samples were then freeze-thawed three times and centrifuged at 13,000 rpm for 20 min at 4°C. Ten μl of supernatant was pipetted in triplicate onto a microtiter plate, and the reaction was initiated by the addition of 90 μl of a 0.0167% (wt/vol) o-dianisidine dihydrochloride and 0.002% (vol/vol) H₂O₂ in PBS. The absorbance was measured for 90 min at 450 nm and plotted in comparison to a standard curve generated using purified MPO (Calbiochem, San Diego, CA) on the same plate (33). Results are expressed as relative units of MPO activity per cornea (1 MPO unit is proportional to 2 × 10⁷ infiltrating neutrophils) (23, 24).

**HRT imaging.** Infected and control mouse corneas were imaged to obtain inflammatory cell counts using noninvasive corneal confocal microscopy. Mice were anesthetized as described above and then placed in an insulated 50-ml centrifuge tube with the bottom cut out to allow the mouse head to protrude for imaging. Eyes were applauded and scanned using a Heidelberg retinal tomographer III with a Rostock cornea module (HRT-RCM) (400- by 400-μm resolution). The mouse holding tube was attached to a gooseneck clamp and positioned such that the surface of the objective cap was perpendicular to the surface normal of the corneal apex. The cornea was applian with enough force to maintain a stable image. Full-thickness volume scans were obtained from multiple locations within the central cornea. The bright, small, light-reflective cells indicate inflammatory cell (most likely neutrophil) infiltration of the infected cornea, as demonstrated by other investigators (34). Inflammatory cells were counted using Image J software (NIH).

**Quantitative real-time PCR.** Whole corneas from infected and control eyes (n = 8 mice/group/time point) were harvested and pooled in RNA lysis buffer at days 1, 3, and 7 p.i. In preliminary experiments, attempts were made to isolate epithelium only. However, due to a very robust infection leading to compromise of the cornea and sometimes perforation, we had to abandon this approach and harvest whole corneas for the experiments. Total RNA was extracted using a Totally RNA total cellular RNA kit from Applied Biosystems (Carlsbad, CA) and quantified using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE). To degrade any contaminating DNA, all samples were treated with DNase (Qiagen, Valencia, CA). Two μg of total RNA was reverse transcribed to cDNA using Moloney murine leukemia virus reverse transcriptase. The 20-μl reaction mixture contained 100 U reverse transcriptase, 10 U RNasin, 1 μg oligo(dT) primers, 10 mM deoxyribonucleotide triphosphates (dNTPs), and reaction buffer (Biochain Institute Inc., Newark, CA). Relative quantitative real-time PCR amplification was performed using SYBR green quantitative PCR Mastermix kits (Stratagene, Santa Clara, CA) with specific primers at a concentration of 10 μM (sequences are presented in Table 1) at optimized concentrations to evaluate the expression of mouse defensins (mBD1, mBD2, mBD3, mBD4, mBD5, mBD6, and mBD14) and CRAMP. The PCR included an initial 10-min denaturation at 95°C. Amplification of the cDNA was performed for 40 cycles: denaturation, 95°C for 30 s; annealing, 56°C for 1 min; and extension, 72°C for 30 s. No-RT and no-template controls were included. Data analysis was performed using the Stratagene Mx3005 software, and dissociation melt curves were analyzed to ensure reaction specificity. Amplified gene products were normalized to RNA polymerase II (RPII), the internal control, and calibrated to uninfected day 0 samples.

### Table 1: Primer sequences

<table>
<thead>
<tr>
<th>Primer</th>
<th>Direction</th>
<th>Sequence (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mBD1</td>
<td>Forward</td>
<td>CTGGGATTTTCTTACCTTCTC</td>
</tr>
<tr>
<td>mBD2</td>
<td>Reverse</td>
<td>CTACCCAGGATGACATCCTC</td>
</tr>
<tr>
<td>mBD3</td>
<td>Forward</td>
<td>GAGATCCTACTTCTCCTGGA</td>
</tr>
<tr>
<td>mBD4</td>
<td>Forward</td>
<td>GCTGTGAAGGACTCCCAT</td>
</tr>
<tr>
<td>mBD5</td>
<td>Reverse</td>
<td>CCTTCTCTTTCGATTCTCCT</td>
</tr>
<tr>
<td>mBD6</td>
<td>Reverse</td>
<td>TACCTGCTTCCTTGCCCATTCC</td>
</tr>
<tr>
<td>mBD14</td>
<td>Forward</td>
<td>TCTGTGTTCTGCCGCTGCT</td>
</tr>
<tr>
<td>CRAMP</td>
<td>Reverse</td>
<td>GCCGGTGAGTTTTCCGAC</td>
</tr>
<tr>
<td>RPII</td>
<td>Forward</td>
<td>CTACACAACCTACAGCCCTCAG</td>
</tr>
</tbody>
</table>

Amplified gene products were normalized to RNA polymerase II (RPII), the internal control, and calibrated to uninfected day 0 samples.
**RESULTS**

**F. solani keratitis in C57BL/6 mice.** Clinical progression of infection, neutrophil recruitment, and fungal load were examined in WT C57BL/6 mice infected with *F. solani*. Fig. 1A shows the mean clinical scores from mice (*n* = 6) examined by a slit lamp. At day 1 p.i., the corneas appeared cloudy with mild surface irregularity and an area of opacity ranging from 25 to 50%, with a mean clinical score of 2.83 ± 0.30. Fig. 1B shows an uninfected eye and the typical appearance of *F. solani* corneal infection seen at day 3 p.i. At this time point, the cornea was cloudy with significant edema, and there were dense infiltrates and a nonuniform opacity covering about 50 to 75% of the cornea. At day 3 p.i., the mean clinical score of 4.33 ± 0.21 was significantly higher than that at day 1 p.i. (*P* ≤ 0.002). Seven days following fungal challenge with *F. solani*, the signs of inflammation receded and there was improvement in the corneal condition, with the mean clinical score of 1.16 ± 0.3 tending toward the baseline. The mean clinical scores of the infected eyes at day 7 p.i. were significantly lower than at days 1 and 3 p.i. (*P* ≤ 0.003).

The number of neutrophils recruited to the site of infection was determined by measuring the relative MPO activity in isolated corneas (Fig. 1C). MPO activity was readily apparent by day 1 p.i. and peaked at day 3 p.i. In keeping with the improved clinical score (Fig. 1A) at day 7 p.i., MPO activity was virtually undetectable above the background (which was normalized to 1). In addition to MPO assays, corneal confocal microscopy, a novel noninvasive technique, was used to provide *in vivo* imaging of the infiltrating cells in the cornea. Images (Fig. 1D) were collected at a depth half the thickness of the cornea. The infiltrating cells were visible as small, highly reflective, roughly circular cells, character-
fungal load was determined by quantifying mRNA and protein expression of selected mRNAs. Relative quantitative RT-PCR and immunostaining were used to compare infected with uninfected controls (data not shown). Significant differences among a scratched but not infected group were noted. As shown in Fig. 1E, levels of recoverable viable fungi were high at days 1 and 3 p.i. However, 7 days following fusarium challenge, the pathogen load decreased significantly. These data were consistent with the aforementioned clinical grading, and MPO data demonstrating worsening of infection over 3 days following recovery. Preliminary experiments comparing clinical score, MPO assay, and viable fungal counts showed no significant difference among a scratched but not infected group of animals and nonscratched and noninfected controls (data not shown).

**Antimicrobial Peptide expression following** F. solani **infection.** Relative quantitative RT-PCR and immunostaining were used to determine mRNA and protein expression of selected murine AMPs following fungal challenge. As shown in Fig. 2, there was an upregulation of all AMPs tested at day 1 and/or 3 p.i. compared to the uninfected controls. mBD3, mBD5, mBD6, and mBD14 mRNA levels peaked at day 1, and those of mBD1 and mBD2 were similar at days 1 and 3 p.i. The expression levels of mBD4 and CRAMP peaked at day 3, and all of the genes tended to the baseline at day 7. The expression levels of CRAMP and mBD14 were significantly notable; at their peak, they were 4.17 ± 0.21 and 4.26 ± 0.17 log2 fold higher than those of the controls (P < 0.04 and P < 0.006, respectively). Despite the significant increase in mBD14, further exploration into its effect was not feasible due to the lack of gene specific reagents. However, having shown significant upregulation of mBD3 (peak 2.62 ± 0.07 log2 fold increase compared to the control on day 1 p.i.; P < 0.0003), mBD4 (peak 3.89 ± 0.29 log2 fold increase compared to the control on day 3 p.i.; P < 0.002), and CRAMP mRNA based on reagent availability and mutant mouse resources, we further investigated these specific AMPs.

**Protein expression of** mBD3, **mBD4, and** CRAMP was examined in corneal sections using immunofluorescent staining. As shown in Fig. 3, there was minimal to no staining in uninfected corneas for mBD3 and mBD4. However, data demonstrated that there was basal expression seen for CRAMP. At days 1 and 3 p.i., mBD3, mBD4, and CRAMP showed a more intense staining in the infected corneal epithelium (Fig. 3). At day 7 p.i., there was no difference seen in the intensity of staining of infected versus control corneas (Fig. 3). These data paralleled the mRNA expression pattern seen in Fig. 2.

**Involvement of** mBD3 **in** F. solani **keratitis.** mBD3 KO and age-matched littermate WT mice were used to investigate the role of mBD3 in the ocular defense mechanism against F. solani infection. As shown in Fig. 4, mBD3 KO mice exhibited enhanced severity of disease compared to their WT controls. At day 1 p.i., infected WT mice demonstrated a cloudy cornea with an intact pupillary margin, mild edema, and about 30 to 40% corneal opacity. In comparison, the infected corneas of KO mice displayed a significantly uniform cloudiness and edema with a uniform opacity covering more than 60% of the central cornea. The mean clinical score was 3.0 ± 0.31 and 4.5 ± 0.64 at day 1 p.i. for WT and mBD3 KO mice, respectively, although this difference did not reach statistical significance (P < 0.06). The progression of infection was significantly greater in the mBD3 KO than the WT animals, with the KO mice demonstrating a much more severe corneal response at day 3 p.i. At this time point, the mean clinical score of the WT mice, which was 4.40 ± 0.24, was significantly lower than that of the mBD3 KO mice, with a score of 6.75 ± 0.48 (P < 0.005). At day 7 p.i., the disease showed significant improvement in the WT animals (clinical score of 1.2 ± 0.37), but corneas of the KO mice worsened (clinical score, 8.75 ± 0.94; P < 0.0005.

**FIG 2** AMP mRNA is upregulated in F. solani keratitis in C57BL/6 mice. mRNA levels for all AMPs tested showed upregulation at day 1 and/or 3 compared to uninfected controls. Data are means ± standard errors of the means (SEM) and are representative of three individual experiments (an asterisk indicates significant difference; P < 0.05).

**FIG 3** Elevated AMP protein expression in F. solani keratitis in C57BL/6 mice. Immunostaining revealed increased mBD3, mBD4, and CRAMP at days 1 and 3 p.i. compared to uninfected control corneas. Representative images of isotype controls at day 3 p.i. using primary host IgG showed no immunopositive staining. AMP-specific staining is shown in red, and DAPI was used to stain the nuclei. All images were taken at x200 magnification. Scale bars represent 40 μm. Images are representative of data from 3 mice per group. The experiment was repeated two times with comparable results.
compared to the WT), demonstrating significant corneal edema and descemetocele formation, leading to perforation in some corneas. The KO animals had a higher mean clinical score at day 7 than at day 1 p.i. ($P < 0.01$). The scores for the KO mice were not significantly different between days 3 and 7 p.i. ($P < 0.10$). This was in contrast to the mBD3 WT animals, which showed recovery from the infection at day 7 p.i. compared to day 1 p.i. ($P < 0.01$) and day 3 p.i. ($P < 0.0005$). Fig. 4B shows representative photographs of infected mBD3 KO and WT controls at day 3 p.i. (C) MPO activity revealed a significantly greater neutrophil recruitment in infected KO than in control animals ($n = 4$). (D) Viable fungal load was significantly greater in the infected KO mice than in the controls ($n = 4$). Data are from a representative experiment, which was repeated twice with comparable results (an asterisk indicates significant difference; $P < 0.05$).

Silencing of mBD4 and its effect on disease progression. As there is no mBD4 knockout mouse line available, to examine the role of this AMP in the progression of $F. solani$ keratitis in vivo, knockdown using siRNA was performed in C57BL/6 mice as described by Wu et al. (24). Relative quantitative RT-PCR and immunostaining were performed at 3 days p.i. to confirm knockdown. As shown in Fig. 5A, at this time there was a significant decrease, of approximately 60%, in mBD4 mRNA expression compared to that of untreated controls and a nonspecific scrambled siRNA control. There was no significant difference between the untreated and scrambled siRNA-treated animals. Immunofluorescence staining 3 days p.i. also indicated a marked decrease in mBD4 protein in specific siRNA-treated eyes compared to scrambled siRNA and untreated controls (Fig. 5B).

The next set of experiments was designed to determine if knockdown of mBD4 had a significant impact on disease severity. The results (Fig. 6) indicated that siRNA-treated mice had more severe signs of corneal disease than the scrambled siRNA-treated and untreated infected controls at days 1 and 3 p.i. As shown in Fig. 6A, the clinical score at day 1 p.i. for mBD4 knockdown animals ($6.67 \pm 0.21$) was significantly greater than that for scrambled siRNA ($3.33 \pm 0.49$; $P < 0.0001$) or untreated infected controls ($3.83 \pm 0.60$; $P < 0.0003$). The clinical scores at day 3 p.i. reflect severe disease progression in the mBD4 siRNA-treated animals ($10.87 \pm 0.48$) compared to their scrambled ($5.83 \pm 0.70$; $P < 0.0002$) and untreated infected controls ($4.67 \pm 0.80$; $P < 0.0005$). Fig. 6B shows representative photographs of control, scrambled siRNA- and mBD4 siRNA-treated mice at day 3 p.i. Corneas in the mBD4 knockdown mice exhibited a uniform opacity covering the entire cornea with significant edema, descemetocele formation, and corneal perforation in some animals, indicating very severe corneal disease. There was no significant difference in clinical score among scrambled and untreated control animals at day 1 ($P < 0.83$) or 3 p.i. ($P < 0.30$). As shown in Fig. 6C, there was significantly higher neutrophil recruitment in the mBD4 siRNA-treated corneas than in the scrambled siRNA and untreated infected control corneas ($P < 0.02$). MPO values in in-

![Graph A](image1.png)

![Graph B](image2.png)

![Graph C](image3.png)

![Graph D](image4.png)

**FIG 4** Involvement of mBD3 in $F. solani$ keratitis. (A) Clinical scores indicated that infected mBD3 KO mice demonstrated a more severe disease and no recovery compared to the WT controls. The short horizontal dashed lines represent the mean clinical score. (B) Representative photographs of infected mBD3 KO and WT controls at day 3 p.i. (C) MPO activity revealed a significantly greater neutrophil recruitment in infected KO than in control animals ($n = 4$). (D) Viable fungal load was significantly greater in the infected KO mice than in the controls ($n = 4$). Data are from a representative experiment, which was repeated twice with comparable results (an asterisk indicates significant difference; $P < 0.05$).
fected corneas of scrambled siRNA- and no-siRNA-treated mice showed no significant difference \((P < 0.15)\). Similarly, the data in Fig. 6D show that the fungal load in mBD4 siRNA-treated mice was significantly higher than that in the scrambled siRNA-treated and untreated infected control animals \((P < 0.03)\). We did not investigate time points longer than 3 days, as the knockdown was effective and, as detailed above, there was a marked difference among control and treated animals.

FIG 5 Evidence of mBD4 knockdown. (A) RT-PCR to confirm \textit{in vivo} silencing of the mBD4 gene at day 3 p.i. Data are expressed as log fold change versus the control ± SEM from a representative experiment \((n = 5)\), repeated 3 times with reproducible results (an asterisk indicates significant difference; \(P < 0.05)\). (B) Immunostaining indicated a significant decrease in protein expression of mBD4 in siRNA-treated animals compared to the infected scrambled siRNA-treated or untreated infected controls. AMP-specific staining is shown in red, and DAPI was used to stain the nuclei. Images are representative of sections from an experiment with 5 mice per group. The experiment was repeated 2 times with comparable results. All images were taken at \(\times 200\) magnification. Scale bars represent 40 \(\mu\)m.

FIG 6 Knockdown of mBD4 increases disease severity. (A) \textit{In vivo} silencing of mBD4 resulted in an increase in the mean clinical score in \textit{F. solani}-infected corneas compared to corneas treated with a scrambled siRNA and untreated controls. The short horizontal dashed lines represent the mean clinical scores. (B) Representative photographs taken at day 3 p.i. of mBD4 siRNA-treated, scrambled siRNA-treated, and untreated infected control animals. (C) Neutrophil recruitment at day 3 p.i. as determined by MPO assay \((n = 5)\). (D) Viable fungal load at day 3 p.i. \((n = 5)\). Data are from a representative experiment, which was repeated 3 times with comparable results (an asterisk indicates significant difference; \(P < 0.05)\).
Involvement of CRAMP in *F. solani* keratitis. To investigate if the induction of CRAMP expression seen in response to fungal challenge was of significance in limiting the severity of the infection, keratitis was compared among CRAMP KO and C57BL/6 control mice. At day 1 p.i., the C57BL/6 mice demonstrated a central corneal opacity occupying about 30% of the cornea, with mild swelling and surface irregularity not seen in to the KO mice. The mean clinical score of the KO mice ($5.83 \pm 0.28$) was significantly greater ($P < 0.005$) than that of C57BL/6 mice ($4.17 \pm 0.24$). At 3 days p.i., the severity of disease was progressive in both C57BL/6 control and KO mice. However, the disease progressed much more rapidly in the KO mice, which exhibited a clinical score of $11.33 \pm 0.30$ compared to a much milder increase to a clinical score of $5.67 \pm 0.20$ in the control mice ($P < 0.001$). At 7 days p.i., clinical scores for the CRAMP-KO mice remained significantly elevated, while the infected corneas of the control mice showed marked signs of improvement and disease resolution. At this time, the mean clinical scores were statistically significantly different, with values of $1.83 \pm 0.64$ and $10.17 \pm 0.68$ for control and KO mice, respectively ($P < 0.0001$). Representative photographs of infected corneas of C57BL/6 control and CRAMP KO mice at day 3 p.i. are shown in Fig. 7B. The number of neutrophils recruited and fungal load were determined on days 1, 3, and 7 p.i. As shown in Fig. 7C, CRAMP KO mice had greater neutrophil recruitment than their infected controls at all three time points, with the MPO activity on days 1, 3, and 7 p.i. being significantly higher in the KO mice ($P < 0.04$). Fig. 7D shows that the KO mice exhibited a statistically significant higher fungal load at days 1, 3, and 7 p.i. ($P < 0.05$, $P < 0.02$, and $P < 0.01$, respectively).
of inflammatory cells, and restore corneal integrity within 7 days after fungal inoculation. This pattern of disease progression and recovery within 7 to 14 days following fungal inoculation is comparable to that seen in other studies using various fungi as the infecting agent in immunocompetent mice (27, 36).

AMP mRNA expression paralleled the clinical course of infection, with all of the β-defensins tested and CRAMP being elevated at 1 and 3 days p.i. and trending toward baseline by day 7 p.i. Reliable protein detection reagents are not available for all of the AMPs we tested, but we were able to confirm the same pattern of expression for mBD3, mBD4, and CRAMP proteins, giving the first indication that β-defensins and CRAMP are important for defense against *F. solani* infection. In contrast to our findings with *F. solani*, in a recent study by Yuan et al., who used *C. albicans* as the infecting agent, the authors studied expression of multiple AMPs but observed an increase only in CRAMP, suggesting differences in the ability of these two pathogens to modulate AMP expression (27). It is also possible that the difference can be attributed to the mouse strains used, as disparate regulation of defensin expression has been reported among BALB/c and C57BL/6 mice in a bacterial keratitis model (24). Owing to the infection-induced damage, we were unable to separate epithelium from the rest of the cornea to a degree suitable for sensitive RT-PCR analysis, limiting our ability to determine the cellular sources of AMP mRNA expression (lack of reliable reagents for protein detection of several murine AMPs also precluded detection by immunostaining). Mouse neutrophils express high levels of CRAMP (31), and we found marked expression of mBD1 but not other defensins by murine neutrophils and macrophages (S. S. Kolar, H. Baidouri, W. Zhang, and A. M. McDermott, presented at the 6th International Conference on the Tear Film and Ocular Surface, Florence, Italy, 23 to 25 September 2010). This suggests that infiltrating inflammatory cells contribute to the upregulation of mBD1 (not pursued due to the current lack of evidence of its antifungal activity against *F. solani*) and CRAMP that we observed, but not to that of mBD2 to mBD6 and mBD14. However, we cannot exclude the possibility that the environment within the fungus-infected cornea upregulated inflammatory cell expression of other AMPs. The advent of improved reagents for AMP protein detection will help shed light on this.

In order to provide firm evidence of involvement of AMPs in defense against fungal keratitis, we took advantage of the availability of two AMP knockout strains and a previously published and proven method to knock down β-defensin expression by siRNA (24, 25). We obtained approximately 60% mBD4 gene knockdown, which is comparable to that observed by Wu et al. (24), and more significantly, we were not able to detect any mBD4 peptide by immunostaining. In stark contrast to the control mice, the mBD3 and CRAMP KO mice and mBD4 knockdown mice all demonstrated much more severe disease with no recovery. The KO and knockdown mice also showed greater neutrophil recruitment than control mice. This may be expected to benefit fungal clearance; however, this was not the case, as KO and knockdown animals demonstrated suboptimal fungal clearance resulting in an increased fungal load compared to the controls. Thus, despite the presence of additional neutrophils in the animals, the absence of specific AMPs compromises the ability of the immune response to kill fusarium. Also, both enhanced neutrophil recruitment and compromised fungal clearance likely contribute to the increased disease severity in the KO and knockdown animals. Taken together, our data suggest that mBD3, mBD4, and CRAMP play a critical role in defense against *F. solani*. Furthermore, our findings are in agreement with those of Gao et al. (28), who showed that CRAMP KO mice were susceptible and had severe disease in response to corneal infection with another fungal pathogen, *C. albicans*.

As noted earlier, AMPs are known for both direct killing abilities and immunomodulatory actions (13, 14). However, it is unclear if our finding of AMPs having a protective role against fungal keratitis is the result of direct fungal killing or the result of immunomodulatory activities, or if it is a net result of both of these factors. A few studies have confirmed direct antifungal activity for some of the AMPs we investigated, including mBD3 and CRAMP (18, 37, 38). Thus, direct killing is likely to be an important mechanism contributing to AMP protective effects in fungal keratitis. AMPs such as CRAMP have been reported to be chemotactic for some immune and inflammatory cells, including neutrophils (39). However, in our model, this effect appears to have little impact, as CRAMP KO mice had significantly greater neutrophil recruitment than controls, suggesting that other chemoattractants, such as keratinocyte chemoattractant (KC), have much greater influence. That the relative importance of chemoattractants may be altered in the KO animals should also be acknowledged. Other immunomodulatory actions that may be of significance are currently being investigated in our laboratory.

A particularly interesting finding from our study is that lack of any of the AMPs we tested was sufficient to result in very severe infection. Thus, for example, despite having normal CRAMP and mBD3, mBD4 knockdown animals were unable to resolve the infection. This is suggestive of a combinatorial effect between these AMPs. In conclusion, while the actual mechanisms have yet to be elucidated, this investigation provides direct *in vivo* evidence that the endogenously expressed β-defensins mBD3 and mBD4 and the cathelicidin CRAMP play a significant role in the host defense response to *F. solani*-induced keratitis. Furthermore, these data provide insight into disease pathogenesis in addition to opening up new opportunities for development of AMP-based therapeutics for the treatment of ocular diseases such as *F. solani* keratitis.

**ACKNOWLEDGMENTS**

This work was supported by NIH EY13175 (A.M.M.), University of Houston College of Optometry (UHCO) Vision Grant to Advance Research (A.M.M.), and NIH EY07551 (UHCO core grant).

We gratefully acknowledge Richard Gallo (UC San Diego) for donating the CRAMP antibody and granting permission for the use of the CRAMP KO mice in a C57BL/6 background, which were kindly provided by Fu Shin Yu (Wayne State University).

We thank Russell Lewis, Alan Burns, Ronald Harwerth, and Rachel Redfern (all at the University of Houston) for their helpful discussions, technical advice, and use of the DeltaVision microscope (A.B.) and HRT equipment (R.H.).

We have no conflicts of interest to declare.

**REFERENCES**


Antimicrobial Peptides in Fusarium solani Keratitis


